Pfizer sues Breckenridge over rheumatoid arthritis drug
Pfizer has sued Breckenridge Pharmaceutical, Pensa Pharma and Laboratorios del Dr Esteve for patent infringement of its drug Xeljanz (tofacitinib).
Xeljanz is a drug given to rheumatoid arthritis patients to help treat moderate to severe pain.
The case, which was filed on Tuesday, March 21 at the US District Court for the District of Delaware, arose after Breckenridge filed an Abbreviated New Drug Application with the Food and Drug Administration.
The company had sought permission to sell generic versions of Pfizer’s Xeljanz, and by doing so would infringe US patent numbers 6,965,027 and 7,301,023, according to Pfizer.
Pfizer has asked the district court for a ruling in its favour, as well as a permanent injunction enjoining Breckenridge from bringing the generics to market.
The company has also asked for an award of damages.
Breckenridge is a wholly-owned subsidiary of Pensa Pharma, while Laboratorios del Dr Esteve manufactures pharmaceutical products distributed by Breckenridge.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk